DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Memantine for Post-Operative Pain Control

Information source: University of Washington
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pain, Post-operative

Intervention: Memantine (Drug); Placebo (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University of Washington

Official(s) and/or principal investigator(s):
Gregory Terman, MD, PhD, Principal Investigator, Affiliation: University of Washington Department of Anesthesiology and Pain Medicine

Overall contact:
Lydia Stout, BA, Phone: 206-914-9253, Email: lstout@uw.edu


Pain is a common element of surgery. Opiates (morphine, oxycodone, hydrocodone, methadone, fentanyl) are very helpful in decreasing pain after surgery. Unfortunately, with repeated use opiates lose their effectiveness, such that patients need to utilize more opiates to

achieve adequate pain relief - a phenomenon called tolerance. Sometimes tolerance to a pain

reliever's effects can develop in just a few hours. It is thought that activation of the N-methyl d-aspartate (NMDA) receptor, a "switch" found on the surface of nerves, is partially responsible for opiate tolerance. Memantine is a medication that limits the activity of NMDA receptors in the brain and spinal cord. It has been used for years to help patients with Alzheimer's Disease. In this study, we will study the effects of memantine when combined with opiate medications to see whether it can increase the effectiveness of opiates for pain after surgery and reduce the side effects caused by opiates (e. g., sedation, nausea, itching).

Clinical Details

Official title: Memantine for Post-Operative Pain Control

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Change in numerical ratings on pain diaries as outpatients (pre and post surgery)

Daily pain numerical ratings at rest and with movement as inpatients.

Total opiate dose via patient controlled IV hydromorphone

Oxycodone dose taken prn

Secondary outcome:

Treatment group differences in side effects (nausea, itching, sedation, urinary retention following foley catheter discontinuation)

Changes in cognitive function, assessed with Digit-Symbol Substitution Test and Trail Making Test B

Changes in pain and quality of life questionnaire responses (SF-McGill-2, Brief Pain Questionnaire, SF-36 v2)


Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- Surgery for total hip replacement, knee replacement OR lumbar spinal fusion

- Taking no opiate medication OR taking opiate medication for at least 6 weeks

Exclusion Criteria:

- History of alcohol or drug abuse

- Clinical diagnosis of Alzheimer's Disease

- Prior adverse reaction to memantine

- Severe renal impairment (creatinine clearance <30 ml/min)

- Inability to give informed consent

Locations and Contacts

Lydia Stout, BA, Phone: 206-914-9253, Email: lstout@uw.edu

University of Washington Medical Center, Seattle, Washington 98195, United States; Recruiting
Lydia Stout, BA, Phone: 206-914-9253, Email: lstout@uw.edu
Additional Information

Related publications:

Grande LA, O'Donnell BR, Fitzgibbon DR, Terman GW. Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient. Anesth Analg. 2008 Oct;107(4):1380-3. doi: 10.1213/ane.0b013e3181733ddd.

Starting date: January 2010
Last updated: June 25, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017